Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lanthe...

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lantheus (LNTH)

Ascendis Pharma ( ($ASND) ) has shared an update. On August 6, 2026, Ascendis Pharma reported new data across its achondroplasia portfolio, highlig...

Ascendis Pharma Posts Strong Achondroplasia Data and Early U.S. YUVIWEL Uptake

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND), Moderna (MRNA) and Stevana...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Moderna (MRNA) and Stevanato Group (STVN)

Ascendis Pharma A/S ($ASND) announced an update on their ongoing clinical study. Ascendis Pharma A/S is running a Phase 3 study called “A Study to ...

Ascendis Pharma Expands Yorvipath Into Adolescents, Raising Long-Term Growth Hopes

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma today and set a price target of $275.00. Skor covers the Healthcare ...

Ascendis Pharma (ASND) Gets a Buy from Morgan Stanley

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. ...

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. (PRME) and Ascendis Pharma (ASND)

Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $345.00. According to TipRanks, Merle is a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$253.42	+1.43%	6.73K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$253.42	+1.4%	6.73K
3
4
5
6

ASND

ASND

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel